Abbott’s new spinal cord stimulation system has been approved by the U.S. Food and Drug Administration. In an press release on August 23, 2022, the medical technology manufacturer announced that their Proclaim Plus cord stimulation system will be available to provide physicians the opportunity to treat multi-site and evolving pain.
Abbott is a global leader in healthcare that works to improve quality of life for people at all phases of life. The company works to provide life-changing technologies in various areas of healthcare including medical equipment, nutritionals, and generic medicines.
According to Abbot, over 50 million Americans suffer from chronic pain, approximately 90 percent of which suffer from pain in at least two or more different parts of the body. As stated by the U.S. Pain Foundation, chronic pain is the primary factor in medical visits and accounts for around $635 billion in annual expenditures associated with healthcare, disability, and lost productivity. The cord stimulation system helps reduce pain for individuals and enhance quality of life. The device is implanted in the body to transmit small electrical pulses to the nerves along the spinal cord, altering how the body interprets pain signals through a process called BurstDR therapy.
“Spinal cord stimulation has provided tremendous relief for patients suffering from chronic pain. With its ability to mimic natural patterns found in the brain, the Abbott BurstDR platform has been a game-changer in this space, helping to not only improve a patient’s ability to perform everyday activities but also relieve the emotional suffering that pain can cause,” explains Steven Falowski, a member of the Argires Marotti Neurosurgical Associates
While BurstDR therapy is effective in reducing pain in a single area, the technology falls short in relieving pain in multiple areas of the body. The Proclaim Plus system works with FlexBurst360 technology to deliver multiple BurstDR stimulations for pain relief in multiple areas of the body. The new device also allows physicians to determine the lowest effective amount of stimulation for each patient and the ability to modify the dose based on the individual patient’s pain needs.
“At Abbott, we are deeply committed to advancing the field of neurostimulation, thus helping people address the challenges they face while managing their chronic pain,” said Pedro Malha, vice president, neuromodulation, Abbott. “Our latest development, Proclaim Plus with FlexBurst360 therapy, is yet another testament of that commitment.”